Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

d in this press release will be achieved; Helix's dependence on its third party service providers, including without limitation, contract research organizations, contract manufacturing organizations, clinical trial consultants, collaborative research consultants, regulatory affairs advisors, and others, whose performance and interdependence can critically affect the Company's performance and the achievement of its milestones; uncertainty whether any of the clinical trials referred to in this news release will be approved, initiated or completed as planned or at all or will achieve expected results; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks, including the possibility that further challenges may arise in connection with the scale-up manufacturing of L-DOS47 or Topical Interferon Alpha-2b, or in connection with the German pharmacokinetic study; the risk of obtaining negative findings or factors that may become apparent during the course of research or development which may result in the discontinuation or delay of the research or development projects; the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks, including without limitation, the risk that three patents for Topical Interferon Alpha-2b will expire in 2013 and no additional patent may be issued, that patent applications may not result in issued patents, that issued patents may be circumvented or struck down, and the risk of potential claims of infringement by the Company of third party intellectual property rights; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; the risk that the Company's supplier for Topical Interferon Alpha-2b may not continue to provide
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... --  Synageva BioPharma Corp. (Synageva) (NASDAQ: ... products for rare diseases, joins the National Organization ... Rare Diseases™ (EURORDIS™), The Global Genes Project™, and ... Day. On the last day of ... participants conduct special events to raise awareness and ...
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... Reportlinker.com announces that a new market research ... Macular Degeneration Therapy Area Pipeline Report ... Macular Degeneration Therapy Area Pipeline Report contains detailed ... report provides insight into the pipeline status of ...
... April 13, 2011 Allscripts (NASDAQ: MDRX ) ... the three months ended March 31, 2011 after the stock ... host a conference call and webcast to discuss the company,s ... on the same day. (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) ...
Cached Medicine Technology:Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 2Reportlinker Adds Macular Degeneration Therapy Area Pipeline Report 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 2Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 3Allscripts to Announce First Quarter 2011 Financial Results on May 5, 2011 4
(Date:2/27/2015)... Daytona Beach, FL (PRWEB) February 27, 2015 ... marketing medical companies, devices and pharmaceuticals, Benedict Advertising ... FL as its newest client. The company’s patented ... is a pain-free, no-stress method of sedation. , ... taking medical patient comfort to a new level, ...
(Date:2/27/2015)... NY (PRWEB) February 27, 2015 The winter ... mold growth and expansion. When mold grows, it can be ... be sure to avoid the consequences of mold growth with ... Long Island, is offering tips on the best ways to ... wet season, which makes perfect conditions for mold to thrive. ...
(Date:2/27/2015)... Vancouver, BC (PRWEB) February 27, 2015 ... exciting overnight deals for couples who wanted to spend ... with the opportunity to get a jump on Valentine’s ... meal and stay in one of their luxurious rooms. ... on February 13, inviting guests for a mouthwatering 3 ...
(Date:2/27/2015)... Florida Hospital North Pinellas is being recognized ... Plus hospital. In order to receive the award, Florida ... all Get With The Guidelines - Stroke Quality Achievement ... achieved 75-percent or higher compliance with six of 10 ... are reporting initiatives to measure quality of care. ...
(Date:2/27/2015)... The UC Davis Huntington’s Disease Center, whose ... a beacon of hope for people with Huntington’s disease ... the national society committed to the values that it ... America — as a Level 1 Huntington’s Disease Center ... service to over 300 families coping with Huntington's disease ...
Breaking Medicine News(10 mins):Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3
... ... and other patient safety information in the public eye , ... San Francisco vary dramatically in terms of how well their ... disability, and expense in our nations, hospitals that is largely preventable.  On ...
... ... patient safety information in the public eye , YONKERS, N.Y. ... Dallas/Fort Worth area vary dramatically in terms of how well their ... disability, and expense in our nations, hospitals that is largely preventable.  On ...
... , Feb. 2 It,s all smiles in Waterbury ... Wolcott Street, Waterbury, CT in the Fair Oaks Shopping Center. ... January 22nd, 2010 in a mission to expand access to ...  Senator J. Hartley and State Representative Selim Noujaim joined the ...
... ... at CoastToCoastMattress.com. Featuring star name brands like Sealy Posturepedic, Simmons Beautyrest and Tempur-Pedic, the ... , ... 2010 -- Coast To Coast Mattress is proud to announce its new mattress lineup, ...
... , ... partnership with SLI-Systems brings advanced Learning Search & Navigation to online health & beauty ... (PRWEB) ... functionality across the Medichest.com platform. , , , , ,Learning Search tracks and ...
... ... the new Wella SP range is set to raise the bar within the hair ... Newport Pagnell, ... world, Wella is at the forefront of hairdressing innovation. The introduction of New SP personalised ...
Cached Medicine News:Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates Vary in San Francisco Hospitals; Three Hospitals Report Zero Infections; Some Hospitals Not Reporting 7Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates in Dallas/Ft. Worth Hospitals Vary Dramatically; Some Hospitals Not Reporting 7Health News:Senator J. Hartley and Representatives Noujaim and Berger Celebrate Kool Smiles Opening in Waterbury 2Health News:Senator J. Hartley and Representatives Noujaim and Berger Celebrate Kool Smiles Opening in Waterbury 3Health News:Coast To Coast Mattress Announces Its New Mattress Lineup 2Health News:Medichest Launches Learning Search 2
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Medicine Products: